Genomic Landscape of Early-Onset and Familial Latin American Parkinson's Patients
This study utilized whole-genome sequencing on 263 early-onset and familial Parkinson's disease patients within the Latin American Research Consortium on the Genetics of PD (LARGE-PD) to identify previously underrepresented pathogenic variants in PD-related and Gaucher's disease genes, thereby expanding the known genetic landscape of the disease in Latin American populations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Parkinson's disease is a condition that slowly disrupts the body's ability to move, often causing tremors, stiffness, and difficulty with balance. While it is most commonly associated with aging, appearing in people over sixty, a smaller group of people develops the disease much earlier, sometimes before their fifties. For these individuals, and for those who have a close relative with the condition, the cause is often written directly into their genetic code. Genes are the biological instructions passed down from parents that determine how our bodies are built and function. In some cases, a specific error in these instructions, known as a genetic variant, can trigger the disease. Scientists have long known that finding these errors is crucial for understanding the disease, but most of what they know comes from studying people of European or Asian ancestry. This leaves a significant gap in knowledge regarding the genetic roots of Parkinson's in Latin American populations, who carry a unique mix of genetic heritage that has been largely overlooked in medical research.
A team of researchers from across the Americas set out to fill this gap by looking closely at the DNA of 256 people from Latin America who had either developed Parkinson's early or had a family history of the disease. These individuals had already been tested using standard genetic screening tools, which are like a checklist of known errors, and had come back negative for the most common causes. The researchers decided to go deeper, using a powerful technology called whole-genome sequencing. This method reads the entire genetic instruction book of a person, rather than just checking a few specific pages. By doing this, they hoped to find rare or unique genetic errors that the standard checklists would miss, specifically those that might explain why these patients developed the disease.
The study revealed that even among people who tested negative on standard screens, a small but meaningful number carried a clear genetic cause for their condition. About 4.7 percent of the participants were found to have a specific, disease-causing error in one of the genes known to be linked to Parkinson's. Another 5.5 percent carried a genetic error in a gene called GBA1. While errors in this gene are primarily known to cause a different condition called Gaucher's disease, they are also a significant risk factor for developing Parkinson's. Additionally, the researchers identified several other genetic variants that were not yet fully understood, known as variants of uncertain significance, which might also play a role in the disease but require more study to confirm.
One of the most important discoveries was that the genetic errors found in this group were often different from those seen in European or Asian populations. The team found several genetic changes that had never been reported before or were extremely rare in global databases. For example, they identified a specific error in the GBA1 gene in a Colombian patient that had no record in any major scientific database. They also found a unique error in a gene called PRKN in a Peruvian patient that appeared to be more common in Latin American populations than anywhere else. These findings suggest that the genetic landscape of Parkinson's in Latin America is distinct and that relying on genetic tests designed for other populations would likely miss these specific causes.
The researchers also looked at how different types of genetic errors appeared in the group. They found that some patients had errors in genes that require two copies of the mistake to cause disease, while others had errors in genes where just one copy was enough. They even found cases where a patient had a large missing piece of a gene, a type of error that standard screening tools often fail to detect. The study highlighted that the whole-genome sequencing approach was able to uncover these complex errors, providing a much clearer picture of the genetic causes than previous methods.
Despite these successes, the study also noted its own limits. The number of people studied, while significant for this type of research, was still relatively small, and the findings were limited to eight countries in the region. Some of the genetic changes identified were still classified as uncertain because there was not enough evidence yet to prove they definitely caused the disease. The researchers emphasized that while their work uncovered new possibilities, further studies are needed to confirm exactly how these genetic errors lead to Parkinson's in these specific populations. They also pointed out that current technology still has trouble reading certain complex parts of the genetic code, meaning there could be more answers waiting to be found.
Ultimately, this work serves as a reminder that genetic diseases do not look the same in every part of the world. By expanding the search to include diverse populations and using more comprehensive tools, scientists are beginning to see the full scope of the genetic factors involved in Parkinson's. The findings suggest that for patients in Latin America, the path to a precise diagnosis may require looking beyond the standard checklists and into the full depth of their genetic code. This shift could lead to better understanding of the disease and, eventually, more targeted treatments for those affected, ensuring that no population is left behind in the quest to understand and cure Parkinson's.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.